Menopur

국가: 아르메니아

언어: 영어

출처: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Download 제품 특성 요약 (SPC)
04-06-2015

유효 성분:

menotropin

제공처:

Ferring GmbH

INN (국제 이름):

menotropin

복용량:

75IU

약제 형태:

powder lyophilized for solution for injection

처방전 유형:

Prescription

제품 특성 요약

                                SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
MENOPUR
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredient: 1 injection bottle with powder contains highly
purified menotrophin
(human menopausal gonadotrophin, HMG) corresponding to FSH 75 IU and
LH 75
IU.
For a full list of excipients see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection
Appearance of powder: white to off-white lyophilisation cake.
Appearance of solvent: clear colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
MENOPUR is indicated for the treatment of female infertility in the
following clinical
situations:
•
Anovulation [including polycystic ovarian disease (PCOD)] in women who
have been
unresponsive to treatment with clomiphene citrate.
•
Controlled ovarian hyperstimulation to induce the development of
multiple follicles
for assisted reproductive technologies (ART) [e.g.: in vitro
fertilisation/embryo
transfer (IVF/ET), gamete intra-Follopian transfer (GIFT) and
intracytoplasmic
sperm injection (ICSI)]
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
METHOD OF ADMINISTRATION
MENOPUR is intended for subcutaneous (s.c.) or intramuscular (i.m.)
injection after
reconstitution with the solvent provided. The powder should be
reconstituted immediately
prior to use. Up to 3 injection bottles of MENOPUR may be dissolved in
1 ml of the
solvent provided. The solution should not be used if it contains
particles or if it is not
clear.
DOSAGE
Dosage regimens described below are identical for subcutaneous and
intramuscular
administration.
There are great inter- and intraindividual variations in the response
of the ovaries to
exogenous gonadotrophins. This makes it impossible to set a uniform
dosage scheme.
The dosage should, therefore, be adjusted individually depending on
the ovarian
response. MENOPUR can be given alone or in combination with a
gonadotrophin-
SPC MENOPUR Germany 2008 English (Menogon HP for AM).doc
1/8
releasing hormone (GnRH) agonist or antagonist. Recommendati
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 러시아어 01-09-2015

이 제품과 관련된 검색 알림

문서 기록보기